ClearRead CT vs PMcardio

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by RIVERAIN TECHNOLOGIES
VS
by Powerful Medical

AI Verdict

ClearRead CT and PMcardio are both AI-powered tools for cardiovascular health, but they focus on different diagnostic modalities. ClearRead CT specializes in analyzing CT scans for pulmonary nodule detection and coronary artery calcification, while PMcardio interprets ECGs for over 50 cardiac conditions, including STEMI and reduced LVEF. Therefore, they are adjacent tools that could complement each other in a comprehensive cardiology workflow rather than being direct competitors.

Choose ClearRead CT if…

Choose ClearRead CT if your radiology department needs to enhance the detection and characterization of pulmonary nodules and analyze coronary artery calcification from CT scans. It's particularly well-suited for improving diagnostic accuracy, reducing reading times, and streamlining workflows in lung cancer screening programs and general cardiothoracic imaging by suppressing vessels and machine noise for a clearer view.

View ClearRead CT →

Choose PMcardio if…

Choose PMcardio if your healthcare setting requires rapid, AI-powered interpretation of ECGs for the assessment of over 50 cardiac conditions, especially at the point of care or in emergency situations. It is ideal for clinicians who need instant, expert-level ECG analysis, including STEMI/OMI detection and reduced LVEF detection, with guideline-adherent treatment recommendations and seamless integration into mobile, web, or EHR/CVIS platforms.

View PMcardio →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature ClearRead CT PMcardio
Pricing Contact for pricing Freemium
Deployment On-premise (stand-alone server, virtual machine) and Cloud Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems
FDA Status 1 AI-estimated Pending AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

PMcardio

PMcardio offers a mobile app and web platform, allowing for instant AI-powered ECG interpretations by simply snapping a photo of a 12-lead ECG. This broad accessibility and ease of use at the point of care, including a free plan, make it highly usable for a wide range of healthcare professionals. ClearRead CT, while integrating seamlessly into PACS, is primarily designed for radiologists reviewing CT scans, which is a more specialized workflow.

Clinical Value

PMcardio

PMcardio has been clinically validated in over 25 studies, demonstrating superior accuracy in detecting over 50 cardiac conditions, including early STEMI detection with twice the sensitivity of standard care and a significant reduction in false STEMI alarms. ClearRead CT also shows strong clinical value with a 29% reduction in missed actionable nodules and 36% faster reading times for radiologists. However, PMcardio's broader impact across various cardiac conditions and its potential for earlier intervention at the point of care give it a slight edge in overall clinical value.

Pricing & Value

PMcardio

PMcardio offers a transparent freemium model with a free plan for individuals and clear pricing for teams and organizations, making it accessible for individual clinicians to try and adopt. ClearRead CT requires contacting the vendor for pricing details, which suggests a less transparent and potentially higher-cost enterprise-focused model. PMcardio's clear pricing structure and free tier offer greater value.

Enterprise Readiness

PMcardio

Both tools demonstrate strong enterprise readiness. ClearRead CT is designed for enterprise-wide deployment, seamlessly integrating with PACS and processing scans from various CT manufacturers. PMcardio also offers enterprise integrations with EHR/CVIS and EMS systems, supports regional data residency, role-based access control, SSO, and full audit trails, and has been adopted by over 50 health systems. PMcardio's comprehensive suite of enterprise features, including unified AI models and end-to-end pathway coverage, gives it an advantage in managing the full cardiac care journey across an organization.

Innovation

PMcardio

PMcardio showcases significant innovation with its AI explainability feature (ECGxplainu2122) using heatmaps, and its ability to detect over 50 cardiac conditions from ECGs, including reduced LVEF and culprit artery prediction. ClearRead CT's patented vessel suppression technology and its FDA clearance for concurrent reading are also innovative, improving nodule conspicuity and reading efficiency. However, PMcardio's visual AI explainability and broader diagnostic scope from a single modality represent a more forward-thinking approach to AI in cardiology.

Support & Docs

PMcardio

PMcardio provides a Help Center with user-friendly tutorials and manuals, FAQs, and regulatory documentation, indicating robust support for its users. ClearRead CT's documentation and support details are less explicitly outlined in the provided information, though its deployment in numerous healthcare institutions suggests adequate underlying support. PMcardio's readily available and detailed support resources give it an edge.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature ClearRead CT PMcardio
Tool Name ClearRead CT PMcardio
Company RIVERAIN TECHNOLOGIES Powerful Medical
Description ClearRead CT is an FDA-cleared AI suite by Riverain Technologies for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans. It improves diagnostic accuracy, reduces reading times, and streamlines radiology workflows through advanced AI and vessel suppression technology. PMcardio is a CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. Clinically validated in more than 25 studies and trusted by over 100,000 clinicians, it delivers rapid, expert-level interpretations, empowering various healthcare professionals to act with confidence at the point of care.
Regulatory Clearance FDA-cleared CE-certified (Class IIb EU MDR). FDA Breakthrough Device Designation for PMcardio STEMI AI ECG Model.
Key Features Pulmonary Nodule Detection (solid, part-solid, ground glass), Patented Vessel Suppression (Clear Visual Intelligence), Nodule Characterization and Measurement (volume, diameter, location, type, depth), Automated Nodule Tracking and Comparison to Prior Exams, Coronary Artery Calcification (CAC) Scoring (ungated, non-contrast CTs), Reduced Reading Time (up to 36%), Improved Detection Accuracy (29% reduction in missed actionable nodules), Seamless PACS Integration / Vendor-neutral processing Instant AI-powered ECG interpretations, Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders), Queen of Heartsu2122 - STEMI and OMI Detection, LVsenseu2122 - Reduced LVEF Detection, ECGxplainu2122 - Visual AI Explainability with heatmaps, Core AI - Detects 36 core diagnoses (arrhythmias, conduction blocks, heart blocks, chamber hypertrophies), Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals, Culprit Artery AI confidence scores with 3D heart visualization
Categories Cardiology AI, Oncology AI, Radiology & Imaging AI Cardiology AI, Clinical Decision Support & Reference
Specialties Cardiology, Pulmonology, Radiology Cardiology, Emergency Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring ClearRead CT and PMcardio.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

ClearRead CT integrates seamlessly into PACS workflows, allowing radiologists to view the AI-generated series alongside original CT scans without needing a separate viewer or login. PMcardio offers enterprise integrations with existing ECG systems, EHR/CVIS, and EMS systems, aiming to unify AI-powered detection, decision support, and care coordination across various cardiac care pathways.
ClearRead CT has been shown to improve detection accuracy by 29% for missed actionable nodules and offers per-nodule sensitivities of 84% for solid, 85% for part-solid, and 67% for ground-glass nodules. PMcardio's AI ECG models have demonstrated 2x sensitivity for early STEMI detection and reduce false STEMI alarms by over 60%. It identifies atrial fibrillation with 98.3% accuracy, on par with board-certified cardiologists.
ClearRead CT is designed for seamless workflow with concurrent reading, suggesting a low learning curve as it integrates directly into existing PACS. PMcardio is designed for speed, simplicity, and clinical confidence, aiming to empower various healthcare professionals with rapid, expert-level interpretations.
PMcardio offers email/help desk support and a help center with user-friendly tutorials and manuals. Information regarding ClearRead CT's specific customer support quality beyond general inquiries is not explicitly detailed in the provided information.
PMcardio is SOC 2 Type II and ISO 27001 certified, ensuring secure data handling and information security management. It also supports regional data residency options for enterprise customers. ClearRead CT operates with VA and other healthcare institutions, implying robust security, but specific details beyond HIPAA compliance are not provided.
ClearRead CT offers enterprise-wide capability on every CT device and universal integration with patient data management programs. PMcardio for Organizations is built for enterprise-ready deployment, connecting to existing systems and scaling across campuses and care settings without custom builds, and includes features like governance and role-based access.
ClearRead CT is specialized for cardiothoracic health, focusing on pulmonary nodule detection and coronary artery calcification analysis in CT scans, utilizing patented vessel suppression technology. PMcardio interprets ECGs to assess over 50 cardiac conditions, including STEMI/OMI and reduced LVEF, and provides AI explainability with heatmaps and guideline-driven treatment recommendations.

Backers

Who funded each tool's parent company.

PMcardio

AI Tool Finder
AI-powered search. Results may not be comprehensive.